Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique.

Wang, Y. H.; Tache, Y.; Harris, A. G.; Kreutner, W.; Daly, Adrian; Wei, J. Y.

doi:10.1111/j.1398-9995.2004.00641.x

Article (Scientific journals)

Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique.

Wang, Y. H.; Tache, Y.; Harris, A. G. et al.

2005 • In Allergy, 60 (1), p. 117-24

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/155140

DOI
10.1111/j.1398-9995.2004.00641.x

PubMed
15575942

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

48-80 Wei et al.pdf

Publisher postprint (347.32 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

p-Methoxy-N-methylphenethylamine/administration & dosage/antagonists & inhibitors/pharmacology

Abstract :

[en] BACKGROUND: Desloratadine is a selective H1-antihistamine used in the treatment of allergic rhinitis and chronic idiopathic urticaria. Desloratadine inhibits the release of allergic inflammatory mediators in vitro. We studied the impact of desloratadine on mast cell degranulation due to activation and re-activation by the secretagogue, compound 48/80. METHODS: Rat peritoneal eluate containing 5-6% mast cells were activated by a low concentration of compound 48/80 in a medium containing the vital fluorescent dye, Sulforhodamine-B (SFRM-B, 200 microg/ml), which is engulfed by activated mast cells. The fluorescent image of activated mast cells was captured digitally and the total fluorescent area was analyzed when desloratadine was applied before or after compound 48/80. RESULTS: Mast cells were not activated by desloratadine (10(-4) M), SFRM-B (200 microg/ml), or diluent alone. A low concentration of compound 48/80 (0.125 microg/ml) induced fluorescence, while mast cells lost fluorescent images due to further degranulation on re-exposure to compound 48/80. Desloratadine (10(-8)-10(-4) M), inhibited compound 48/80-induced mast cell degranulation in a concentration-dependent manner. Desloratadine also reduced the loss of fluorescent images due to re-exposure to compound 48/80. CONCLUSIONS: Desloratadine may have a mast cell stabilizing effect at low concentrations in response to repeated mast cell activation in vitro.

Disciplines :

Immunology & infectious disease

Author, co-author :

Wang, Y. H.

Tache, Y.

Harris, A. G.

Kreutner, W.

Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie

Wei, J. Y.

Language :

English

Title :

Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique.

Publication date :

2005

Journal title :

Allergy

ISSN :

0105-4538

eISSN :

1398-9995

Publisher :

Wiley-Blackwell, Oxford, United Kingdom

Volume :

Issue :

Pages :

117-24

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 30 August 2013

Statistics

Number of views

60 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 1997;99:155-160.
Ishizaka T, Ishizaka K. Activation of mast cells for mediator release through IgE receptors. Prog Allergy 1984;34: 188-235.
Williams CM, Galli SJ. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 2000;105:847-859.
Goitsuka R, Kanazashi H, Sasanuma H, Fujimura Y, Hidaka Y, Tatsuno A et al. A BASH/SLP-76-related adaptor protein MIST/Clnk involved in IgE receptor-mediated mast cell degranulation. Int Immunol 2000;12:573-580.
Zhang J, Berenstein E, Siraganian RP. Phosphorylation of Tyr342 in the linker region of Syk is critical for Fcepsilon RI signaling in mast cells. Mol Cell Biol 2002;22:8144-8154.
Chahdi A, Fraundorfer PF, Beaven MA. Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins. J Pharmacol Exp Ther 2000;292:122-130.
Chahdi A, Mousli M, Landry Y. Substance P-related inhibitors of mast cell exocytosis act on G-proteins or on the cell surface. Eur J Pharmacol 1998;341:329-335.
Senyshyn J, Baumgartner RA, Beaven MA. Quercetin sensitizes RBL-2H3 cells to polybasic mast cell secretagogues through increased expression of Gi GTP-binding proteins linked to a phospholipase C signaling pathway. J Immunol 1998;160:5136-5144.
Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory potential. Allergy 2002;57:287-296.
Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003;112:15-22.
Packard KA, Khan MM. Effects of histamine on Th1/Th2 cytokine balance. Int Immunopharmacol 2003;3:909-920.
Bakker RA, Schoonus SB, Smit MJ, Timmerman H. Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma-and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001;60:1133-1142.
Hu Q, Deshpande S, Irani K, Zieglstein RC. [Ca2+]i oscillation frequency regulates agonist-stimulated NF-κB transcriptional activity. J Blol Chem 1999;274:33995-33998.
Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G. Loratadine and desethoxylcarbonylloratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997;27:559-567.
Lippert U, Kruger-Krasagakes S, Moller A, Kiessling U, Czarnetzki BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995;4:272-276.
Lippert U, Moller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000;9:118-124. Erratum in: Exp Dermatol 2002;11:386.
Lippert U, Moller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000;9:118-124. Erratum in: Exp Dermatol 2002;11:386.
Wei JY, Go VL, Tache Y, Kruger L. Evidence for uptake of vital dye by activated rat peritoneal mast cells: an in vitro imaging study. Neuroimage 1994;1:313-324.
Wang YH, Go VL, Wu SV, Wei JY. Stem cell factor alters membrane potential of purified peritoneal mast cells in culture. Am J Physiol 1997;272:C1017- C1024.
Bray RE, VAN Arsdel PP Jr. In vitro histamine release from rat mast cells by chemical and physical agents. Pro Soc Exp Blol Med 1961;106:255-259.
Krüger P-G, Mahata SK, Helle K.B. Catestatin (Chromogranin A344-358) stimulates release of histamine from rat pleural and peritoneal mast cells. Ann NY Acad Sci 2002;971:349-351.
Baltzly R, Buck JS, DE Beer EJ, Web FJ. A family of long-acting depressors. J Am Chem Soc 1949;71:1301-1305.
Paton WDM. Compound 48/80: a potent histamine liberator. Br J Pharmacol 1951;6:499-508.
Fawcett DW. Cytological and pharmacological observations on the release of histamine by mast cells. J Exp Med 1954;100:217-224.
Uvnäs B, Thon IL. Evidence for enzymatic histamine release from isolated rat mast cells. Exp Cell Res 1961;23:4-47.
Hino RH, Lau CK, Read GW. The site of action of the histamine releaser compound 45/80 in causing mast cell degranulation. J Pharmacol Exp Ther 1977;200:658-663.
Grossman N. Effect of TMB-8 on histamine release from isolated rat mast cells. Int Arch Allergy Appl Immunol 1986;79:253-258.
Slutsky B, Jarvis D, Bibb P, Feldberg RS, Cochrane DE. Viability and recovery from degranulation of isolated rat peritoneal mast cells. Exp Cell Res 1987;168:63-78.
Kawasaki Y, Saitoh T, Okabe T, Kumakura K, Ohara-Imaizumi M. Visualization of exocytotic secretory processes of mast cells by fluorescence techniques. Biochim Biophys Acta 1991;1067:71-80.
Moritz KU, Ambrosius H. Sulforhodamine B, a good labeling stain suitable for immunology. Acta Histochem 1964;13:191-194.
Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, Malolepszy J et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001;413:420-425.
Marone G, Genovese A, Granata F, Forte V, Detoraki A, DE Paulis A et al. Pharmacological modulation of human mast cells and basophils. Clin Exp Allergy 2002;32:1682-1689.
Page S, Ammit AJ, Black JL, Armour CL. Human mast cell and airway smooth muscle cell interactions: implications for asthma. Am J Physiol Lung Cell Mol Physiol 2001;281:L1313-L1323.
Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993;365:340-343.
Van Cauwenberge P. Advances in allergy management. Allergy 2002;57: 29-36.
Ring J, Hein R, Gauger A. Desloratadine in the treatment of chronic idiopathic urticaria. Allergy 2001;56:28-32.
Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001;56:7-13.
Bachert C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy 2002;57:13-18.
Bryce PJ, Geha R, Oettgen HC. Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J Allergy Clin Immunol 2003;112: 149-158.